Thomas Foltynie Mrcp

List of Publications by Year
in descending order

282 papers	22,958 citations	9264 74 h-index	11308 136 g-index
295 all docs	295 docs citations	295 times ranked	19807 citing authors

#	Article	IF	Citations
1	Balance between competing spectral states in subthalamic nucleus is linked to motor impairment in Parkinsonâ€™s disease. Brain, 2022, 145, 237-250.	7.6	25
2	European clinical guidelines for Tourette syndrome and other tic disordersâ€"version 2.0. Part IV: deep brain stimulation. European Child and Adolescent Psychiatry, 2022, 31, 443-461.	4.7	26
3	Quantifying Stridor associated with Parkinsonism and Deep Brain Stimulationâ€•a case report. Movement Disorders Clinical Practice, 2022, 9, 91-94.	1.5	0
4	Computer-vision based method for quantifying rising from chair in Parkinson's disease patients. Intelligence-based Medicine, 2022, 6, 100046.	2.4	13
5	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in <scp><i>GBA</i></scp> Mutation Carriers. Annals of Neurology, 2022, 91, 424-435.	5.3	46
6	A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. Focus (American Psychiatric Publishing), 2022, 20, 160-169.	0.8	3
7	Volitional Control of Brain Motor Activity and Its Therapeutic Potential. Neuromodulation, 2022, 25, 1187-1196.	0.8	6
8	Conflict Detection in a Sequential Decision Task Is Associated with Increased Cortico-Subthalamic Coherence and Prolonged Subthalamic Oscillatory Response in the Î² Band. Journal of Neuroscience, 2022, 42, 4681-4692.	3.6	2
9	How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?. Movement Disorders, 2022, 37, 1581-1592.	3.9	29
10	Combining biomarkers for prognostic modelling of Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	1.9	9
11	The Impact of Type 2 Diabetes in Parkinson's Disease. Movement Disorders, 2022, 37, 1612-1623.	3.9	30
12	Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson's Disease Dementia: A 36â€‰Months Follow Up Study. Movement Disorders Clinical Practice, 2022, 9, 765-774.	1.5	3
13	European Academy of Neurology/Movement Disorder Societyâ€European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. Movement Disorders, 2022, 37, 1360-1374.	3.9	49
14	Basal Ganglia Pathways Associated With Therapeutic Pallidal Deep Brain Stimulation for Tourette Syndrome. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 961-972.	1.5	12
15	Pedunculopontine Nucleus Deep Brain Stimulation for Parkinsonian Disorders: A Case Series. Stereotactic and Functional Neurosurgery, 2021, 99, 287-294.	1.5	12
16	Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated â€œBiphasicâ€likeâ€•Dyskinesia with Pallidal Deep Brain Stimulation. Movement Disorders Clinical Practice, 2021, 8, 273-274.	1.5	7
17	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	3.9	101
18	Non-invasive intervention for motor signs of Parkinsonâ€™s disease: the effect of vibratory stimuli. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 109-110.	1.9	3

#	Article	IF	Citations
19	Stimulation Sweet Spot in Subthalamic Deep Brain Stimulation â€“ Myth or Reality? A Critical Review of Literature. Stereotactic and Functional Neurosurgery, 2021, 99, 425-442.	1.5	12
20	Long-term success of low-frequency subthalamic nucleus stimulation for Parkinsonâ€™s disease depends on tremor severity and symptom duration. Brain Communications, 2021, 3, fcab165.	3.3	5
21	The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs and Aging, 2021, 38, 355-373.	2.7	8
22	Might it Be Possible to Assess Rigidity in PD Patients Remotely?. Movement Disorders Clinical Practice, 2021, 8, 489-490.	1.5	0
23	Inhibitory Control on a Stop Signal Task in Tourette Syndrome before and after Deep Brain Stimulation of the Internal Segment of the Globus Pallidus. Brain Sciences, 2021, 11, 461.	2.3	4
24	Reply to Comment on: Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated â€œBiphasicâ€Likeâ€•Dyskinesia with Pallidal Deep Brain Stimulation. Movement Disorders Clinical Practice, 2021, 8, 814-815.	1.5	0
25	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	9.0	95
26	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinsonâ€™s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The â€˜Exenatide-PD3â€™ study. BMJ Open, 2021, 11, e047993.	1.9	32
27	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
28	A practical guide to troubleshooting pallidal deep brain stimulation issues in patients with dystonia. Parkinsonism and Related Disorders, 2021, 87, 142-154.	2.2	1
29	Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurology, The, 2021, 20, 559-572.	10.2	136
30	Video-Based Analyses of Parkinsonâ€™s Disease Severity: A Brief Review. Journal of Parkinson's Disease, 2021, 11, S83-S93.	2.8	30
31	Reply to: Subthalamic Nucleus Deep Brain Stimulation as Rescue Therapy for Levodopa Carbidopa Intestinal Gelâ€“Associated Biphasicâ€Like Dyskinesias. Movement Disorders Clinical Practice, 2021, 8, 1157-1158.	1.5	0
32	â€œRealâ€Lifeâ€•Remote Dystonia Assessment: Feasibility, Accuracy, and Practice Implications. Movement Disorders Clinical Practice, 2021, 8, 1269-1271.	1.5	1
33	Neural signatures of hyperdirect pathway activity in Parkinsonâ€™s disease. Nature Communications, 2021, 12, 5185.	12.8	65
34	The Parkinsonâ€™s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinsonâ€™s Disease in Patients and their Carers. Journal of Parkinson's Disease, 2021, 11, 1309-1323.	2.8	8
35	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinsonâ€™s Disease. Sensors, 2021, 21, 5437.	3.8	26
36	Cortical connectivity of the nucleus basalis of Meynert in Parkinsonâ€™s disease and Lewy body dementias. Brain, 2021, 144, 781-788.	7.6	24

#	Article	IF	Citations
37	Dynamic Network Connectivity Reveals Markers of Response to Deep Brain Stimulation in Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2021, 15, 729677.	2.0	10
38	Disease modifying therapies for Parkinson's disease: Novel targets. Neuropharmacology, 2021, 201, 108839.	4.1	4
39	Endurance of Short Pulse Width Thalamic Stimulation Efficacy in Intention Tremor. Stereotactic and Functional Neurosurgery, 2021, 99, 281-286.	1.5	3
40	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
41	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 77, 163-169.	2.2	11
42	Short Versus Conventional Pulseâ€Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison. Movement Disorders, 2020, 35, 101-108.	3.9	23
43	Understanding the Links Between Cardiovascular Disease and Parkinson's Disease. Movement Disorders, 2020, 35, 55-74.	3.9	71
44	Motor Complications in Parkinson's Disease: 13â€Year Followâ€up of the CamPaIGN Cohort. Movement Disorders, 2020, 35, 185-190.	3.9	39
45	Reply: Pathophysiology of gait disorders induced by bilateral globus pallidus interna stimulation in dystonia. Brain, 2020, 143, e4-e4.	7.6	1
46	Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinsonâ€™s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study. BMJ Open, 2020, 10, e038911.	1.9	18
47	Longitudinal functional connectivity changes related to dopaminergic decline in Parkinsonâ€™s disease. NeuroImage: Clinical, 2020, 28, 102409.	2.7	17
48	Novel Programming Features Help Alleviate Subthalamic Nucleus Stimulationâ€Induced Side Effects. Movement Disorders, 2020, 35, 2261-2269.	3.9	20
49	Ropinirole, a dopamine agonist with high D3 affinity, reduces proactive inhibition: A double-blind, placebo-controlled study in healthy adults. Neuropharmacology, 2020, 179, 108278.	4.1	14
50	Identification of nonlinear features in cortical and subcortical signals of Parkinson's Disease patients via a novel efficient measure. NeuroImage, 2020, 223, 117356.	4.2	9
51	Diabetes medications and risk of Parkinsonâ€™s disease: a cohort study of patients with diabetes. Brain, 2020, 143, 3067-3076.	7.6	108
52	Structural connectivity predicts clinical outcomes of deep brain stimulation for Tourette syndrome. Brain, 2020, 143, 2607-2623.	7.6	50
53	Resting state activity and connectivity of the nucleus basalis of Meynert and globus pallidus in Lewy body dementia and Parkinson's disease dementia. NeuroImage, 2020, 221, 117184.	4.2	15
54	Not only loud but also intelligible. EClinicalMedicine, 2020, 24, 100456.	7.1	1

#	Article	IF	Citations
55	Entraining Stepping Movements of Parkinson's Patients to Alternating Subthalamic Nucleus Deep Brain Stimulation. Journal of Neuroscience, 2020, 40, 8964-8972.	3.6	12
56	Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone. Movement Disorders Clinical Practice, 2020, 7, 955-960.	1.5	6
57	Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience. Progress in Brain Research, 2020, 252, 493-523.	1.4	26
58	Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinsonâ€™s Disease. Drugs, 2020, 80, 775-796.	10.9	23
59	Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease. Parkinsonism and Related Disorders, 2020, 76, 49-53.	2.2	13
60	Subthalamic nucleus deep brain stimulation for Parkinsonâ€™s disease: current trends and future directions. Expert Review of Medical Devices, 2020, 17, 1063-1074.	2.8	11
61	Diabetes, BMI, and Parkinson's. Movement Disorders, 2020, 35, 201-203.	3.9	14
62	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
63	Seeing Through the FOG?. Movement Disorders, 2020, 35, 3-4.	3.9	0
64	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations. JAMA Neurology, 2020, 77, 427.	9.0	213
65	The Association Between Type 2 Diabetes Mellitus and Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 775-789.	2.8	101
66	A common polymorphism in <i>SNCA</i> is associated with accelerated motor decline in <i>GBA</i>-Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 673-674.	1.9	9
67	Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. Brain Stimulation, 2020, 13, 1031-1039.	1.6	39
68	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The <scp>COVID</scp>â€19 Experience. Movement Disorders Clinical Practice, 2020, 7, 361-372.	1.5	91
69	Impact of <i>GBA1</i> variants on long-term clinical progression and mortality in incident Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 695-702.	1.9	48
70	Subthalamic Nucleus Deep Brain Stimulation in Parkinsonâ€™s Disease: Valuable Programming Insights from Anecdotal Observations. Stereotactic and Functional Neurosurgery, 2020, 98, 62-64.	1.5	0
71	Post hoc analysis of the Exenatideâ€<scp>PD</scp> trialâ€"Factors that predict response. European Journal of Neuroscience, 2019, 49, 410-421.	2.6	43
72	Genetic analysis of Mendelian mutations in a large UK population-based Parkinsonâ€™s disease study. Brain, 2019, 142, 2828-2844.	7.6	62

#	Article	IF	Citations
73	Glycolysis as a therapeutic target for Parkinson's disease. Lancet Neurology, The, 2019, 18, 1072-1074.	10.2	15
74	The effects of deep brain stimulation of the pedunculopontine nucleus on cognition in Parkinson's disease and Progressive Supranuclear Palsy. Clinical Parkinsonism & Related Disorders, 2019, 1, 48-51.	0.9	4
75	Globus pallidal deep brain stimulation for Tourette syndrome: Effects on cognitive function. Parkinsonism and Related Disorders, 2019, 69, 14-18.	2.2	5
76	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
77	Dopaminergic Modulation of Sensory Attenuation in Parkinson's Disease: Is There an Underlying Modulation of Beta Power?. Frontiers in Neurology, 2019, 10, 1001.	2.4	3
78	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
79	A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. Biological Psychiatry, 2019, 85, 726-734.	1.3	152
80	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
81	The long-term outcome of impulsive compulsive behaviours in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
82	Deep brain stimulation has state-dependent effects on motor connectivity in Parkinsonâ€™s disease. Brain, 2019, 142, 2417-2431.	7.6	33
83	Impairment in Theory of Mind in Parkinsonâ€™s Disease Is Explained by Deficits in Inhibition. Parkinson's Disease, 2019, 2019, 1-8.	1.1	14
84	The BRadykinesia Akinesia INcoordination (BRAIN) Tap Test: Capturing the Sequence Effect. Movement Disorders Clinical Practice, 2019, 6, 462-469.	1.5	23
85	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Movement Disorders, 2019, 34, 1505-1515.	3.9	15
86	Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1078-1090.	1.9	81
87	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. Parkinsonism and Related Disorders, 2019, 65, 55-61.	2.2	14
88	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	1.9	29
89	Chronic Subthalamic Nucleus Stimulation in Parkinson's Disease: Optimal Frequency for Gait Depends on Stimulation Site and Axial Symptoms. Frontiers in Neurology, 2019, 10, 29.	2.4	11
90	Beta synchrony in the cortico-basal ganglia network during regulation of force control on and off dopamine. Neurobiology of Disease, 2019, 127, 253-263.	4.4	16

#	Article	IF	Citations
91	Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology, 2019, 15, 234-242.	10.1	250
92	Effect of Low versus High Frequency Subthalamic Deep Brain Stimulation on Speech Intelligibility and Verbal Fluency in Parkinsonâ€™s Disease: A Double-Blind Study. Journal of Parkinson's Disease, 2019, 9, 141-151.	2.8	22
93	Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease. JAMA Neurology, 2019, 76, 420.	9.0	169
94	Glucagonâ€like Peptides (GLPâ€1) Perspectives in Synucleinopathies Treatment. Movement Disorders Clinical Practice, 2018, 5, 255-258.	1.5	7
95	Mechanisms Underlying Decision-Making as Revealed by Deep-Brain Stimulation in Patients with Parkinsonâ€™s Disease. Current Biology, 2018, 28, 1169-1178.e6.	3.9	66
96	Connectivity derived thalamic segmentation in deep brain stimulation for tremor. NeuroImage: Clinical, 2018, 18, 130-142.	2.7	154
97	Features of <i>GBA</i>-associated Parkinsonâ€™s disease at presentation in the UK <i>Tracking Parkinsonâ€™s</i> study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 702-709.	1.9	103
98	Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome. JAMA Neurology, 2018, 75, 353.	9.0	186
99	Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia. JAMA Neurology, 2018, 75, 169.	9.0	112
100	Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinsonâ€™s disease. Brain, 2018, 141, 7-10.	7.6	12
101	Effects of pedunculopontine nucleus stimulation on human bladder function. Neurourology and Urodynamics, 2018, 37, 726-734.	1.5	16
102	¹¹Câ€PE2I and ¹⁸Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	3.9	45
103	Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review. Movement Disorders, 2018, 33, 10-20.	3.9	166
104	Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology, 2018, 136, 260-270.	4.1	68
105	Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. BJPsych Open, 2018, 4, 404-410.	0.7	3
106	Developing and validating Parkinsonâ€™s disease subtypes and their motor and cognitive progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1279-1287.	1.9	116
107	Therapies to Slow, Stop, or Reverse Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, S115-S121.	2.8	19
108	Modulation of Beta Bursts in the Subthalamic Nucleus Predicts Motor Performance. Journal of Neuroscience, 2018, 38, 8905-8917.	3.6	113

#	Article	IF	Citations
109	Parkinsonian signs in patients with cervical dystonia treated with pallidal deep brain stimulation. Brain, 2018, 141, 3023-3034.	7.6	33
110	Association of Optic Pathways and Brain Structure With Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementiaâ€"Reply. JAMA Neurology, 2018, 75, 896.	9.0	1
111	Alternating Modulation of Subthalamic Nucleus Beta Oscillations during Stepping. Journal of Neuroscience, 2018, 38, 5111-5121.	3.6	66
112	Highâ€frequency peripheral vibration decreases completion time on a number of motor tasks. European Journal of Neuroscience, 2018, 48, 1789-1802.	2.6	15
113	Drug Repurposing in Parkinsonâ€™s Disease. CNS Drugs, 2018, 32, 747-761.	5.9	40
114	Noninvasive options for â€˜wearing-offâ€™ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. Neurodegenerative Disease Management, 2018, 8, 349-360.	2.2	22
115	Standardised Neuropsychological Assessment for the Selection of Patients Undergoing DBS for Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-13.	1.1	11
116	Impact of Subthalamic Deep Brain Stimulation Frequency on Upper Limb Motor Function in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 267-271.	2.8	10
117	What Effects Might Exenatide have on Non-Motor Symptoms in Parkinsonâ€™s Disease: A Post Hoc Analysis. Journal of Parkinson's Disease, 2018, 8, 247-258.	2.8	47
118	The Effect of Short Pulse Width Settings on the Therapeutic Window in Subthalamic Nucleus Deep Brain Stimulation for Parkinsonâ€™s disease. Journal of Parkinson's Disease, 2018, 8, 273-279.	2.8	28
119	Changing of the guard: reducing infection when replacing neural pacemakers. Journal of Neurosurgery, 2017, 126, 1165-1172.	1.6	27
120	Thalamicâ€Caudal Zona Incerta Deep Brain Stimulation for Refractory Orthostatic Tremor: A Report of 3 Cases. Movement Disorders Clinical Practice, 2017, 4, 105-110.	1.5	5
121	Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 176-185.	1.9	70
122	Differences in <scp>MDS</scp>â€<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice, 2017, 4, 536-544.	1.5	65
123	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. Parkinsonism and Related Disorders, 2017, 40, 40-46.	2.2	15
124	<scp>l</scp>-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease. Movement Disorders, 2017, 32, 874-883.	3.9	37
125	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
126	Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease. Movement Disorders, 2017, 32, 1174-1182.	3.9	52

#	Article	IF	Citations
127	Subthalamic nucleus beta and gamma activity is modulated depending on the level of imagined grip force. Experimental Neurology, 2017, 293, 53-61.	4.1	31
128	Stimulating at the right time: phase-specific deep brain stimulation. Brain, 2017, 140, 132-145.	7.6	213
129	Comparison of oscillatory activity in subthalamic nucleus in Parkinson's disease and dystonia. Neurobiology of Disease, 2017, 98, 100-107.	4.4	51
130	GBA-Associated Parkinsonâ€™s Disease: Progression in a Deep Brain Stimulation Cohort. Journal of Parkinson's Disease, 2017, 7, 635-644.	2.8	44
131	Uncovering the underlying mechanisms and whole-brain dynamics of deep brain stimulation for Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 9882.	3.3	79
132	16â€...A randomised controlled trial of deep brain stimulation in obsessive compulsive disorder: a comparison of ventral capsule/ventral striatum and subthalamic nucleus targets. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A8.2-A9.	1.9	3
133	Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations. Movement Disorders, 2017, 32, 1333-1335.	3.9	9
134	Subthalamic deep brain stimulation sweet spots and hyperdirect cortical connectivity in Parkinson's disease. NeuroImage, 2017, 158, 332-345.	4.2	197
135	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1664-1675.	13.7	527
136	Refining the Deep Brain Stimulation Target within the Limbic Globus Pallidus Internus for Tourette Syndrome. Stereotactic and Functional Neurosurgery, 2017, 95, 251-258.	1.5	33
137	Loss of phosphodiesterase 4 in Parkinson disease. Neurology, 2017, 89, 586-593.	1.1	30
138	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. Movement Disorders Clinical Practice, 2017, 4, 509-516.	1.5	35
139	Oscillatory Beta Power Correlates With Akinesiaâ€Rigidity in the Parkinsonian Subthalamic Nucleus. Movement Disorders, 2017, 32, 174-175.	3.9	52
140	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
141	Technologies Assessing Limb Bradykinesia in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 65-77.	2.8	50
142	Subthalamic Nucleus Deep Brain Stimulation in Parkinsonâ€™s Disease: The Effect of Varying Stimulation Parameters. Journal of Parkinson's Disease, 2017, 7, 235-245.	2.8	81
143	Is Exenatide a Treatment for Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2017, 7, 451-458.	2.8	29
144	PO088â€...Nigral iron susceptibility in parkinsonâ€™s disease: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A34.4-A35.	1.9	0

#	Article	IF	Citations
145	Apathy and Reduced Speed of Processing Underlie Decline in Verbal Fluency following DBS. Behavioural Neurology, 2017, 2017, 1-10.	2.1	15
146	Functional Connectivity of the Pedunculopontine Nucleus and Surrounding Region in Parkinson's Disease. Cerebral Cortex, 2017, 27, 54-67.	2.9	22
147	Distinct mechanisms mediate speed-accuracy adjustments in cortico-subthalamic networks. ELife, 2017, 6, .	6.0	71
148	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. PLoS Medicine, 2017, 14, e1002314.	8.4	152
149	Subthalamic nucleus gamma activity increases not only during movement but also during movement inhibition. ELife, 2017, 6, .	6.0	41
150	Variation in Recent Onset Parkinsonâ€™s Disease: Implications for Prodromal Detection. Journal of Parkinson's Disease, 2016, 6, 289-300.	2.8	21
151	The Parkinsonian Subthalamic Network: Measures of Power, Linear, and Non-linear Synchronization and their Relationship to L-DOPA Treatment and OFF State Motor Severity. Frontiers in Human Neuroscience, 2016, 10, 517.	2.0	28
152	The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work?. Frontiers in Neuroscience, 2016, 10, 170.	2.8	55
153	The Use of Deep Brain Stimulation in Tourette Syndrome. Brain Sciences, 2016, 6, 35.	2.3	43
154	Bilateral Deep Brain Stimulation of the Globus Pallidus Pars Interna in a Patient with Variant Ataxiaâ€Telangiectasia. Movement Disorders Clinical Practice, 2016, 3, 405-408.	1.5	9
155	Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1183-1190.	1.9	24
156	Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1388-1389.	1.9	199
157	Letter to the Editor: A paradigm shift toward MRI-guided and MRI-verified DBS surgery. Journal of Neurosurgery, 2016, 124, 1135-1138.	1.6	16
158	Subthalamic nucleus deep brain stimulation induces impulsive action when patients with Parkinsonâ€™s disease act under speed pressure. Experimental Brain Research, 2016, 234, 1837-1848.	1.5	35
159	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 96-101.	2.2	46
160	Challenges in detecting disease modification in Parkinson's disease clinical trials. Parkinsonism and Related Disorders, 2016, 32, 1-11.	2.2	52
161	Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia. Movement Disorders, 2016, 31, 143-146.	3.9	26
162	A genomic approach to therapeutic target validation identifies a glucose-lowering <i>GLP1R</i> variant protective for coronary heart disease. Science Translational Medicine, 2016, 8, 341ra76.	12.4	100

#	Article	IF	Citations
163	Human subthalamic nucleusâ€“medial frontal cortex theta phase coherence is involved in conflict and error related cortical monitoring. NeuroImage, 2016, 137, 178-187.	4.2	66
164	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	3.9	49
165	Vocal tics in Tourette's syndrome. Lancet Neurology, The, 2016, 15, e1.	10.2	4
166	Bilateral adaptive deep brain stimulation is effective in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 717-721.	1.9	269
167	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
168	Deep brain stimulation modulates synchrony within spatially and spectrally distinct resting state networks in Parkinsonâ€™s disease. Brain, 2016, 139, 1482-1496.	7.6	213
169	Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology, 2016, 86, 986-993.	1.1	42
170	Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1034-1036.	1.9	9
171	Subthalamic nucleus phaseâ€“amplitude coupling correlates with motor impairment in Parkinsonâ€™s disease. Clinical Neurophysiology, 2016, 127, 2010-2019.	1.5	159
172	Analysis of simultaneous MEG and intracranial LFP recordings during Deep Brain Stimulation: a protocol and experimental validation. Journal of Neuroscience Methods, 2016, 261, 29-46.	2.5	52
173	The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discovery Today, 2016, 21, 802-818.	6.4	247
174	Decisions Made with Less Evidence Involve Higher Levels of Corticosubthalamic Nucleus Theta Band Synchrony. Journal of Cognitive Neuroscience, 2016, 28, 811-825.	2.3	18
175	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	6.2	333
176	Subcortical evoked activity and motor enhancement in Parkinson's disease. Experimental Neurology, 2016, 277, 19-26.	4.1	10
177	Decoding gripping force based on local field potentials recorded from subthalamic nucleus in humans. ELife, 2016, 5, .	6.0	41
178	Writer's Cramp as the First Symptom of Spinocerebellar Ataxia 14. Movement Disorders Clinical Practice, 2015, 2, 41-42.	1.5	3
179	Tracking Parkinsonâ€™s: Study Design and Baseline Patient Data. Journal of Parkinson's Disease, 2015, 5, 947-959.	2.8	64
180	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. American Journal of Human Genetics, 2015, 96, 938-947.	6.2	109

#	Article	IF	Citations
181	Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments. Journal of Neurology, 2015, 262, 2583-2595.	3.6	34
182	Tremor Reduction by Deep Brain Stimulation Is Associated With Gamma Power Suppression in Parkinsonâ€™s Disease. Neuromodulation, 2015, 18, 349-354.	0.8	60
183	Do we need to revise the tripartite subdivision hypothesis of the human subthalamic nucleus (STN)? Response to Alkemade and Forstmann. NeuroImage, 2015, 110, 1-2.	4.2	33
184	Subthalamic Nucleus Local Field Potential Activity Helps Encode Motor Effort Rather Than Force in Parkinsonism. Journal of Neuroscience, 2015, 35, 5941-5949.	3.6	39
185	Varying time-course of effects of high frequency stimulation of sub-regions of the globus pallidus in patients with parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 597-602.	2.2	11
186	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. Brain, 2015, 138, 3003-3015.	7.6	100
187	Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurology, The, 2015, 14, 595-605.	10.2	155
188	Parkinsonâ€™s disease dementia: a neural networks perspective. Brain, 2015, 138, 1454-1476.	7.6	333
189	Deep brain stimulation of the subthalamic nucleus: histological verification and 9.4-T MRI correlation. Acta Neurochirurgica, 2015, 157, 2143-2147.	1.7	11
190	Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speedâ€“accuracy instructions. Neuropsychologia, 2015, 75, 577-587.	1.6	39
191	The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nature Reviews Neurology, 2015, 11, 25-40.	10.1	211
192	Tourette syndrome deep brain stimulation: A review and updated recommendations. Movement Disorders, 2015, 30, 448-471.	3.9	236
193	Can Parkinsonâ€™s disease be cured by stimulating neurogenesis?. Journal of Clinical Investigation, 2015, 125, 978-980.	8.2	10
194	The Safety of Using Body-Transmit MRI in Patients with Implanted Deep Brain Stimulation Devices. PLoS ONE, 2015, 10, e0129077.	2.5	46
195	Influence of Single Nucleotide Polymorphisms in <i>COMT</i>, <i>MAO-A</i> and <i>BDNF</i> Genes on Dyskinesias and Levodopa Use in Parkinson's Disease. Neurodegenerative Diseases, 2014, 13, 24-28.	1.4	56
196	In a Rush to Decide: Deep Brain Stimulation and Dopamine Agonist Therapy in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 579-583.	2.8	9
197	Perceptual decision-making in patients with Parkinsonâ€™s disease. Journal of Psychopharmacology, 2014, 28, 1149-1154.	4.0	22
198	The nature of tremor circuits in parkinsonian and essential tremor. Brain, 2014, 137, 3223-3234.	7.6	90

#	Article	IF	Citations
199	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 2014, 137, 1481-1495.	7.6	258
200	Predictive factors of speech intelligibility following subthalamic nucleus stimulation in consecutive patients with Parkinson's disease. Movement Disorders, 2014, 29, 532-538.	3.9	79
201	Lysine 27 Ubiquitination of the Mitochondrial Transport Protein Miro Is Dependent on Serine 65 of the Parkin Ubiquitin Ligase. Journal of Biological Chemistry, 2014, 289, 14569-14582.	3.4	152
202	Human Subthalamic Nucleus in Movement Error Detection and Its Evaluation during Visuomotor Adaptation. Journal of Neuroscience, 2014, 34, 16744-16754.	3.6	61
203	Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. JAMA Neurology, 2014, 71, 83.	9.0	257
204	Midline Frontal Cortex Low-Frequency Activity Drives Subthalamic Nucleus Oscillations during Conflict. Journal of Neuroscience, 2014, 34, 7322-7333.	3.6	133
205	Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic. Alzheimer's and Dementia, 2014, 10, S38-46.	0.8	35
206	Resting state functional MRI in Parkinsonâ€™s disease: the impact of deep brain stimulation on â€˜effectiveâ€™ connectivity. Brain, 2014, 137, 1130-1144.	7.6	196
207	Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1419-1425.	1.9	151
208	Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation. Journal of Visualized Experiments, 2014, , .	0.3	19
209	Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2014, 4, 337-344.	2.8	206
210	Adaptive deep brain stimulation in advanced Parkinson disease. Annals of Neurology, 2013, 74, 449-457.	5.3	1,046
211	Successful pallidal deep brain stimulation in 15-year-old with Tourette syndrome: 2-year follow-up. Journal of Neurology, 2013, 260, 2417-2419.	3.6	20
212	The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders, 2013, 28, 232-236.	3.9	121
213	The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia?. Neuroscience and Biobehavioral Reviews, 2013, 37, 2676-2688.	6.1	145
214	Understanding DCM: Ten simple rules for the clinician. NeuroImage, 2013, 83, 542-549.	4.2	65
215	Glucocerebrosidase mutations influence the natural history of Parkinsonâ€™s disease in a community-based incident cohort. Brain, 2013, 136, 392-399.	7.6	266
216	Phase dependent modulation of tremor amplitude in essential tremor through thalamic stimulation. Brain, 2013, 136, 3062-3075.	7.6	80

#	Article	IF	Citations
217	Deep brain stimulation as a treatment for chorea-acanthocytosis. Journal of Neurology, 2013, 260, 303-305.	3.6	19
218	Parkinsonâ€™s disease: an update on pathogenesis and treatment. Journal of Neurology, 2013, 260, 1433-1440.	3.6	29
219	Subthalamic nucleus gamma oscillations mediate a switch from automatic to controlled processing: A study of random number generation in Parkinson's disease. NeuroImage, 2013, 64, 284-289.	4.2	24
220	Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain, 2013, 136, 374-384.	7.6	239
221	The Risk of Hardware Infection in Deep Brain Stimulation Surgery Is Greater at Impulse Generator Replacement than at the Primary Procedure. Stereotactic and Functional Neurosurgery, 2013, 91, 56-65.	1.5	129
222	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
223	Subthalamic Nucleus Local Field Potential Activity during the Eriksen Flanker Task Reveals a Novel Role for Theta Phase during Conflict Monitoring. Journal of Neuroscience, 2013, 33, 14758-14766.	3.6	99
224	The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1258-1264.	1.9	534
225	TRACKING PARKINSON'S (THE PROBAND STUDY)â€“INTERIM REPORT FROM THE FIRST 1000 CASES. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.70-e2.	1.9	0
226	Dopamine Agonists Rather than Deep Brain Stimulation Cause Reflection Impulsivity in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 139-144.	2.8	39
227	Genotype and phenotype in Parkinson's disease: Lessons in heterogeneity from deep brain stimulation. Movement Disorders, 2013, 28, 1370-1375.	3.9	77
228	How can we judge the â€˜long termâ€™ outcomes of novel interventions in Parkinsonâ€™s disease?. NeuroReport, 2013, 24, 1005-1009.	1.2	1
229	Commentary. Movement Disorders, 2013, 28, 739-739.	3.9	0
230	Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. Movement Disorders, 2013, 28, 1874-1877.	3.9	30
231	Imageâ€guided and imageâ€verified deep brain stimulation. Movement Disorders, 2013, 28, 254-254.	3.9	13
232	Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. PLoS ONE, 2013, 8, e69190.	2.5	55
233	Exenatide and the treatment of patients with Parkinsonâ€™s disease. Journal of Clinical Investigation, 2013, 123, 2730-2736.	8.2	361
234	Short and Long Term Outcome of Bilateral Pallidal Stimulation in Chorea-Acanthocytosis. PLoS ONE, 2013, 8, e79241.	2.5	44

#	Article	IF	Citations
235	Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. Journal of Neurosurgery, 2012, 116, 84-94.	1.6	331
236	Movement-Related Changes in Local and Long-Range Synchronization in Parkinson's Disease Revealed by Simultaneous Magnetoencephalography and Intracranial Recordings. Journal of Neuroscience, 2012, 32, 10541-10553.	3.6	176
237	Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism. Brain, 2012, 135, 148-160.	7.6	141
238	Subthalamic nucleus activity optimizes maximal effort motor responses in Parkinsonâ€™s disease. Brain, 2012, 135, 2766-2778.	7.6	59
239	Imageâ€verified deep brain stimulation reduces risk and cost with no apparent impact on efficacy. Movement Disorders, 2012, 27, 1585-1586.	3.9	18
240	The surgical anatomy of the pedunculopontine nucleus cannot be disputed, buried or exhumed. Acta Neurochirurgica, 2012, 154, 1531-1533.	1.7	0
241	Analysis of ATP13A2 in large neurodegeneration with brain iron accumulation (NBIA) and dystonia-parkinsonism cohorts. Neuroscience Letters, 2012, 523, 35-38.	2.1	15
242	Confirmation of functional zones within the human subthalamic nucleus: Patterns of connectivity and sub-parcellation using diffusion weighted imaging. NeuroImage, 2012, 60, 83-94.	4.2	294
243	Reply: Deep brain stimulation in Huntington's disease: A 4-year follow-up case report. Movement Disorders, 2012, 27, 808-808.	3.9	1
244	Decision making, impulsivity, and addictions: Do Parkinson's disease patients jump to conclusions?. Movement Disorders, 2012, 27, 1137-1145.	3.9	85
245	Uncertainty, misunderstanding and the pedunculopontine nucleus. Acta Neurochirurgica, 2012, 154, 839-841.	1.7	5
246	Deep brain stimulation in the treatment of chorea. Movement Disorders, 2012, 27, 357-363.	3.9	61
247	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Movement Disorders, 2012, 27, 312-315.	3.9	56
248	Therapeutic Subthalamic Nucleus Deep Brain Stimulation Reverses Cortico-Thalamic Coupling during Voluntary Movements in Parkinson's Disease. PLoS ONE, 2012, 7, e50270.	2.5	66
249	An approach to deep brain stimulation for severe treatment-refractory Tourette syndrome: the UK perspective. British Journal of Neurosurgery, 2011, 25, 38-44.	0.8	70
250	Resting oscillatory cortico-subthalamic connectivity in patients with Parkinsonâ€™s disease. Brain, 2011, 134, 359-374.	7.6	387
251	The natural history of treated Parkinson's disease in an incident, community based cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1112-1118.	1.9	200
252	Gender distribution of patients with Parkinsonâ€™s disease treated with subthalamic deep brain stimulation; a review of the 2000â€“2009 literature. Parkinsonism and Related Disorders, 2011, 17, 146-149.	2.2	49

#	Article	IF	Citations
253	MRI-Guided Subthalamic Nucleus Deep Brain Stimulation without Microelectrode Recording: Can We Dispense with Surgery under Local Anaesthesia?. Stereotactic and Functional Neurosurgery, 2011, 89, 318-325.	1.5	82
254	The Factor Structure of the UPDRS as an Index of Disease Progression in Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 75-82.	2.8	15
255	Clinical Safety of Brain Magnetic Resonance Imaging with Implanted Deep Brain Stimulation Hardware: Large Case Series and Review of the Literature. World Neurosurgery, 2011, 76, 164-172.	1.3	97
256	Gene therapy: a viable therapeutic strategy for Parkinsonâ€™s disease?. Journal of Neurology, 2011, 258, 179-188.	3.6	25
257	Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. Acta Neurochirurgica, 2011, 153, 2357-2360.	1.7	37
258	Deep brain stimulation for Gilles de la Tourette syndrome: A case series targeting subregions of the globus pallidus internus. Movement Disorders, 2011, 26, 1922-1930.	3.9	103
259	Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease. Movement Disorders, 2011, 26, 1835-1843.	3.9	39
260	Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease. Movement Disorders, 2011, 26, 2434-2436.	3.9	35
261	Skewering the Subthalamic Nucleus via a Parietal Approach. Stereotactic and Functional Neurosurgery, 2011, 89, 70-75.	1.5	6
262	Minimizing Brain Shift in Stereotactic Functional Neurosurgery. Operative Neurosurgery, 2010, 67, ons213-ons221.	0.8	46
263	Improving Targeting in Image-Guided Frame-Based Deep Brain Stimulation. Operative Neurosurgery, 2010, 67, ons437-ons447.	0.8	50
264	Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1383-1389.	1.9	177
265	Surgical management of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 903-914.	2.8	72
266	Early and marked benefit with GPi DBS for Lubag syndrome presenting with rapidly progressive lifeâ€threatening dystonia. Movement Disorders, 2009, 24, 1710-1712.	3.9	48
267	Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinsonâ€™s Disease. Journal of Neurology, 2009, 256, 493-498.	3.6	141
268	No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinsonâ€™s disease. Journal of Neurology, 2009, 256, 132-133.	3.6	7
269	The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain, 2009, 132, 2958-2969.	7.6	842
270	Tau and Î±â€synuclein in susceptibility to, and dementia in, Parkinson's disease. Annals of Neurology, 2007, 62, 145-153.	5.3	256

#	Article	IF	Citations
271	Cognitive Deficits and Psychosis in Parkinson???s Disease. CNS Drugs, 2006, 20, 477-505.	5.9	115
272	A case of voltage-gated potassium channel antibody-related limbic encephalitis. Nature Clinical Practice Neurology, 2006, 2, 339-343.	2.5	19
273	Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Annals of Neurology, 2005, 57, 564-567.	5.3	178
274	A genome wide linkage disequilibrium screen in Parkinsonâ€™s disease. Journal of Neurology, 2005, 252, 597-602.	3.6	7
275	The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinsonâ€™s disease. Journal of Neurology, 2005, 252, 833-838.	3.6	102
276	The cognitive ability of an incident cohort of Parkinsonâ€™s patients in the UK. The CamPaIGN study. Brain, 2004, 127, 550-560.	7.6	605
277	The future challenges in Parkinson?s Disease. Journal of Neurology, 2004, 251, 361-365.	3.6	3
278	Differentiation and migration of long term expanded human neural progenitors in a partial lesion model of Parkinsonâ€™s disease. International Journal of Biochemistry and Cell Biology, 2004, 36, 702-713.	2.8	73
279	A genome-wide screen for association in Hungarian multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 84-87.	2.3	15
280	A whole genome association study in multiple sclerosis patients from north Portugal. Journal of Neuroimmunology, 2003, 143, 116-119.	2.3	13
281	Vascular Parkinsonism: A Review of the Precision and Frequency of the Diagnosis. Neuroepidemiology, 2002, 21, 1-7.	2.3	52
282	The heterogeneity of idiopathic Parkinson's disease. Journal of Neurology, 2002, 249, 138-145.	3.6	198